Bangladesh Beximco Starts Drugs Exports to Jordan (Bangladesh)
This article was originally published in PharmAsia News
Bangladesh's top drug maker, Beximco Pharmaceuticals announced Sept. 30 that it will soon begin exporting medicines to Jordan. So far, Beximco has received approval for four different treatments, with several other applications in the works. Jordan has a pharmaceutical market worth an estimated $315 million that primarily relies on imports. The country also boasts a strong infrastructure, a well-regulated healthcare system, and strong trading partnerships throughout the Middle East. Representatives for Beximco say these factors make the country an ideal entry point for the company into the region's markets. (Click here for more
You may also be interested in...
COVID-driven supply shortages were both the cause of and solution to production deficiencies for manufacturers of neuromuscular blocking agents; US FDA is permitting Mylan, Gland, and Fresenius Kabi to distribute vecuronium bromide and rocuronium bromide even though they do not have the ‘paralyzing agent’ warning on the caps since the products are in high demand at ICUs. The appropriately embossed caps were unavailable due to supply chain disruptions caused by the pandemic.
The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new selective estrogen receptor degraders for HER2-negative breast cancer.
Medtronic has agreed to licensing and development agreements with cash-strapped surgical robotics company Titan receiving payments up to $31m pending certain milestones.